Since the IPO in 1992, investor relations have been our highest priority and are directly assigned to the Management Board. The objective of our IR work is to present as true and fair a picture as possible of the company and its potential for development in its markets, therefore creating a good basis of information on which to arrive at a sustainable decision to invest in our company. A transparent information policy, our commitment to the Austrian Corporate Governance Code and our active approach to investors are integral components of this strategy.
BWT SHAREHOLDER INFORMATION 2009 for the 3rd quarter
BWT fit for pharma expansion after 3rd quarter
- Sales € 296.9 million (-4.7%)
- EBIT € 24.6 million (-4.7%)
- Net result € 22.2 million (+19.0%)
- Gearing 3.0% (23.8% as of Sept. 30, 2008)
- Equity ratio 52.9% (46.2% as of Sept. 30, 2008)
- New share buyback program
Download:
BWT Quarterly Report Q3/2009